Constitutive E-selectin expression on dermal microvascular endothelial cells plays a critical role in mediating rolling adhesive interactions of human skin-homing T cells and in pathologic accumulation of lymphocytes in skin. The major E-selectin ligand on human skin-homing T cells is cutaneous lymphocyte-associated antigen (CLA), a specialized glycoform of P-selectin glycoprotein ligand-1 (PSGL-1) defined by monoclonal antibody HECA-452. Since HECA-452 reactivity, and not PSGL-1 polypeptide itself, confers the specificity of human T cells to enter dermal tissue, inhibition of HECA-452 expression is a potential strategy for modulating lymphocyte migration to skin. In this study, we examined the efficacy of several well-characterized metabolic inhibi-
IntroductionTissue-specific migration of lymphocytes in neoplastic and inflammatory processes is critically dependent on the expression of cell membrane adhesion molecules that regulate adhesive interactions with target tissue endothelium. Skin disorders, including cutaneous T-cell lymphomas, cutaneous graft-versus-host disease (GVHD), and other inflammatory diseases (eg, psoriasis), are mediated by infiltrations of skin-homing T cells that express cutaneous lymphocyte-associated antigen (CLA). [1][2][3][4][5][6][7][8][9][10] CLA is a sialyl Lewis X-like carbohydrate epitope displayed on the mucinlike molecule Pselectin glycoprotein ligand-1 (PSGL-1) recognized by the rat monoclonal antibody HECA-452. 2,11,12 CLA functions as the P-selectin ligand and the principal E-and L-selectin ligand on human skin-homing T cells; specifically, the presence of HECA-452 epitopes on PSGL-1 directly correlates with the capacity of skin-homing memory T cells (including skin-disease-related lymphocytes) to bind E-selectin, which is constitutively expressed on dermal microvasculature. 2,11,13 CLA-E-selectin binding interactions mediate lymphocyte trafficking to skin, and therefore, posttranslational glycosylations on skin-homing leukocytes represent a potential therapeutic target for controlling cutaneous tropism.The ␣2,3 sialyltransferase, ST3Gal IV, and ␣1,3 fucosyltransferases, FucTIV and FucTVII, expressed in human skin-homing lymphocytes are responsible for synthesizing terminal sialofucosylations, recognized by HECA-452, that serve as E-selectinbinding determinants on PSGL-1. 14-23 These terminal sialyl Lewis X structures are expressed on poly-N-acetyllactosamines [(Gal1,4GlcNAc1,3) n ] found on core 2 serine/threonine (O)-linked glycans and asparagine (N)-linked glycans displayed by PSGL-1. [24][25][26][27][28][29][30] Although the majority of sialyl Lewis X epitopes appear to reside on PSGL-1 O-glycans, there are 3 potential sites for N-glycosylation and sialyl Lewis X decoration. 30 Consequently, interfering with the synthesis of O-glycans or N-glycans or of poly-N-acetyllactosamine structures on either O-or N-glycans (or both) would prevent the synthesis of HECA-452 epitopes and could dampen the E-selectin-binding function of PSGL-1 (CLA) on skin-homing leukocytes. The pu...